Early-Stage cancer drug study halted after just 3 patients
NCT ID NCT04674748
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 31 times
Summary
This early-phase study aimed to test the safety and dosing of an experimental drug called INCB086550 in Japanese adults with advanced solid tumors that had stopped responding to standard treatments. Only 3 participants were enrolled before the study was terminated early. The main goal was to monitor side effects and find a safe dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center Hospital
Tokyo, 104-0045, Japan
-
National Cancer Center Hospital - East
Chiba, 277-8577, Japan
Conditions
Explore the condition pages connected to this study.